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Abstract
Background: People who self-harm are at high risk for future suicide and often suffer considerable emotional
distress. Depression is common among people who self-harm and may be an underlying driver of self-harm
behaviour. Self-harm is often repeated, and risk of repetition is highest immediately after an act of self-harm. Readily
accessible brief talking therapies show promise in helping people who self-harm, but further evaluation of these
approaches is needed. A brief talking therapy intervention for depression and self-harm has been designed for use
in a community setting. This mixed methods feasibility study with repeated measures will examine the feasibility
and acceptability of the Community Outpatient Psychological Engagement Service for Self-Harm (COPESS) for
people with self-harm and depression in the community, compared to routine care.
Methods: Sixty participants with a history of self-harm within the last six months, who are also currently depressed,
will be recruited to take part in a feasibility single-blind randomised controlled trial (RCT). Participants will be
randomised 1:1 to receive COPESS plus treatment as usual (TAU) or TAU alone. Recruitment will be via General
Practitioners (GP) and self-referral. Assessment of feasibility and acceptability will be assessed via quantitative and
qualitative methods including measures of recruitment and retention to the feasibility trial, participants’ experience
of therapy, completion/completeness of outcome measures at relevant time-points and completion of a service use
questionnaire.
Discussion: The results will indicate whether it is feasible to conduct a definitive full trial to determine whether
COPESS is a clinically and cost effective intervention for people who self-harm in the community. Qualitative and
quantitative data will in addition help identify potential strengths and/or challenges of implementing brief
community-based interventions for people who self-harm.
Trial registration: NCT04191122 registered 9th December 2019.
Background
Self-harm is a public health priority and people with a
history of self-harm feature in the Suicide Prevention
Strategy for England as a priority group [1–3]. Self-harm
defined as any intentional act of self-injury or self-
poisoning regardless of motivation or suicidal intent [4]
is often a sign of underlying distress, predictive of psy-
chological problems and associated with premature
death by suicide and other causes [5–9]. In England,
there are over 200,000 self-harm presentations to hos-
pital emergency departments (ED) annually [10–12].
Rates of self-harm in primary care are estimated to be
double the rates of hospital admissions and the
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prevalence of self-harm in the community is substan-
tially higher [13–16].
General Practitioners are often the first point of con-
tact for mental health issues in the community, but re-
port feeling under skilled in relation to managing self-
harm [17, 18]. National policy and guidance [4] empha-
sises the need for rapid access to community-based ser-
vices for self-harm, but referral pathways and treatment
options are often unclear to patients and health profes-
sionals alike [19].
Symptoms of depression are common among people
who self-harm and are thought to be related to the ini-
tial occurrence and subsequent repetition of self-harm
[20, 21]. However, talking therapies designed for treating
depression do not necessarily reduce or improve self-
harm-related outcomes [22]. It has been argued that
self-harm interventions need to be specifically developed
for this context [23, 24].
Talking therapies that target the psychological pro-
cesses underlying self-harm have been shown to reduce
repetition of self-harm [25–27] and depressive symp-
toms [27, 28], and there is some evidence that cognitive
behavioural therapy (CBT) and psychodynamic interper-
sonal therapy (PIT) were effective in reducing some self-
harm behaviours in the short-term [28]. The Cochrane
review [25] makes a distinction between brief therapies,
usually provided for people who present following self-
harm in acute distress, and higher-intensity therapies
(such as Dialectical Behavioural Therapy [29]) which are
designed to help people who struggle with self-harm and
multiple co-existing life problems. The evidence base
around brief therapies that benefit people with recent
self-harm remains limited and further evaluation is
needed. The Community Outpatient Psychological En-
gagement for Self-harm Service (COPESS) belongs to
this category of interventions. It is a low-intensity ther-
apy, which addresses causes that precipitate self-harm
and associated symptoms of depression.
COPESS is a modified version of psychodynamic-
interpersonal therapy (PIT), has been evaluated in
two randomised trials for self-harm [27] and used
in NHS self-harm services in England [30]. PIT has
undergone two modifications for the purposes of
this feasibility trial. Elements of another closely
linked therapy, Cognitive Analytic Therapy (CAT)
[31], have been added to the intervention with the
use of visual mapping and a focus on identifying
“exits” or solutions to clients’ difficulties. Previous
evaluation of this therapy approach within an ED
setting found that 64% of referred individuals
attended at least one therapy session, with nearly
half (n = 26, 49%) attending all four sessions [30].
There was also evidence of a reduction in clients’
distress over the therapy period.
The Normalisation Process Theory (NPT) [31] is an
action theory that identifies key characteristics and
mechanisms that can help or hinder the integration of
new healthcare interventions. It has been effectively used
to aid intervention development as well as evaluating
and understanding implementation processes them-
selves. In particular, NPT offers a set of conceptual tools
to aid understanding of implementation as a dynamic
process [31]. NPT will be used to inform this feasibility
study about the potential for normalisation of integrat-
ing the COPESS intervention into community health
settings.
Aims
The aim of this study is to examine the feasibility and
acceptability of delivering the COPESS intervention in a
community setting, as well as to assess the feasibility and
acceptability of the trial procedures themselves, with a
view to future implementation in a full-scale efficacy
trial. The key outcomes concern methodological, pro-
cedural and clinical uncertainties [32–34] such as esti-
mates of recruitment and retention rates; feasibility and
acceptability of data collection instruments and data col-
lection procedures; feasibility, acceptability and safety of
the intervention.
Methods and analysis
This protocol conforms to guidelines presented in the
Consolidated Standards of Reporting Trials (CONSORT)
[35] 2010 statement extension for randomised feasibility
studies and clinical trial protocols. A Patient Advisory
Group (PAG) was set up at an early stage to provide in-
put into all aspects of the study. The PAG includes pa-
tients, carers and people with lived-experience of self-
harm and represents a diverse range of perspectives and
insight. Guidance will be sought from the PAG on a
regular basis to ensure the perspectives of service users
are embedded throughout the life of the study and be-
yond. The project has been fully reviewed by a research
ethics committee who have scrutinised our procedures
for managing risk and distress, and Health Research Au-
thority approval has been granted.
Design
The study is a single-blind, randomised controlled feasi-
bility trial with an embedded qualitative process evalu-
ation. Participants will be randomised 1:1 to receive
COPESS plus treatment-as-usual (TAU) or TAU alone.
Eligibility criteria
Participants with current depression and recent self-
harm will be recruited through participating GP prac-
tices and self-referral (see Fig. 1). GPs of participants
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who self-refer will be informed of their participation, in
line with participant consent procedures.
Inclusion criteria
– Adult or adolescent, aged 16 years or over.
– Self-harm within the last 6 months (self-reported)
defined as an act of direct, intentional harm to
oneself irrespective of suicidal intent
– A score of 14 or greater on the Beck Depression
Inventory-II (BDI-II) [36]
– Help-seeking, via attendance at GP practices or self-
referral into the trial.
Exclusion criteria
– Non-English speaking.
– Diagnosed with an intellectual disability as
determined by review of clinical notes - the therapy
has not yet been adapted for working with this
population.
– Unable or unwilling to give written informed
consent to participate.
– Currently receiving face-to-face psychological talking
therapy for self-harm (potential participants will not
be excluded due to group counselling or regular
nurse appointments).
Recruitment
The eligible population are adults or adolescents who
self-harm and are resident in Liverpool, a large city in
the North of England. There are approximately 300–350
hospital presentations for self-harm per annum to the
Royal Liverpool Hospital [37]. The ‘iceberg’ model of
self-harm suggests self-harm by people who present to
hospital are only a small proportion of self-harm overall
with most going unreported in the community [15].
Hospital figures based on routinely collected clinical data
tend to underestimate self-harm presentations by around
40–50% [10]; we therefore estimate at least double the
number of self-harm cases that presented to hospital
emergency departments are likely to occur in the com-
munity each year [12–16].
Participants will be identified and recruited via GP
practices by three methods:
1. Practice database searches with GP letters
informing them of the study;
2. Participants consulting with their GP for self-harm;
3. Advertising material displayed where participants
may seek help for self-harm within community set-
tings, e.g. primary care, student counselling services,
walk-in centres and Talk Liverpool (Talk Liverpool
is a free NHS service that offers psychological ther-
apies in Liverpool to adults who are feeling anxious
or depressed).
Recruitment of GP practices
The National Institute for Health Research Clinical Re-
search Network (NIHR CRN) will assist with recruit-
ment of GP practices. For the feasibility trial, 12 medium
to large research-active GP practices will be identified
and invited to participate. Initially, four recruited prac-
tices will be monitored for number of participants
Fig. 1 Recruitment flow chart
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recruited into the feasibility trial over a 2-month period.
We will add four more GP practices if required and fol-
low the same procedure. If recruitment targets are not
being met after 4 months then the final four GP prac-
tices will be included. All GPs within participating prac-
tices will be informed about the project and given an
information pack (including information on ethical ap-
proval, funding and study documents) by the researcher.
This may be followed up by a telephone/skype/face-to-
face contact from the researcher to ascertain level of
interest, and if appropriate, to arrange to discuss the
study in more detail.
Trial-GP
One GP at each practice will be identified as the (trial-
specific GP) and have a portion of their time costed into
the trial to make referrals, and encourage and support
others at the practice to refer into the study.
Recruitment of participants
Once potential participants have been identified and
matched against the eligibility criteria, they will be sent
an introductory pack that comprises: an explanatory let-
ter from the practice; a participant information sheet
about the study, an expression of interest form; and, a
freepost return envelope by DocMail.
The recruitment procedure was reviewed by the PAG
who believed they would be acceptable to potential par-
ticipants. Although many trials rely on clinicians asking
patients directly if they wish to take part we recognise
this may create unwanted pressure for patients. In con-
trast, a letter provides greater control to the patient who
then has the choice of whether to respond or not. To
ensure people who self-harm are not negatively affected
by receiving a letter from their GP Practice, the partici-
pant information sheet highlights details of non-NHS or-
ganisation such as Samaritans and Papyrus that patients
can access regardless of whether they participate in the
trial or not. Patients are informed they are free to with-
draw from this study at any time, without giving a rea-
son, and without it effecting their legal right or clinical
care in any way.
Any self-referrals who contact the study team directly
via community advertising methods (e.g. posters) will be
asked to provide details of their GP. The study team will
contact the GP to make them aware of the study and
confirm patient eligibility, identify any potential risks
and allow disclosures or adverse events during the study
to be captured.
Recruitment rates from the different recruitment
routes will be monitored, including numbers of people
who do/do not respond to initial letters, proportion of
eligible participants consented and the number of partic-
ipants recruited against targets. Qualitative interviews
with participants in the therapy arm and in the TAU
arm will identify any concerns or issues relating to the
study procedures. Where individuals choose not to re-
spond to the letters and therefore do not provide con-
sent to take part in the study or to be contacted by the
study team, it is not possible to interview them or other-
wise assess their experience of being contacted. How-
ever, throughout the study, adverse events and event
reactions will be carefully monitored, including any ad-
verse reactions linked to recruitment procedures. Hence,
the necessary steps to monitor and identify any potential
harms arising from the study will be completed through-
out the feasibility trial.
Informed consent, screening and baseline
After receiving an expression of interest from potential
participants, a brief telephone/video call (e.g. Skype)
screening interview with one of the research team will
determine eligibility. Contact will be attempted a max-
imum of three times before the patient is listed as “un-
contactable”. Feedback from the PAG advised that
participants be given a choice of communication
methods (e.g. telephone/video call/face-to-face). Those
who meet the eligibility criteria will be invited for a
baseline assessment. Eligibility and safety checks will be
undertaken by the Research Assistant through contact-
ing the potential participants’ GP or nurse practitioner,
with the patient’s consent. Signed informed consent will
be sought from all eligible participants at the initial base-
line meeting.
Reasons for non-participation and withdrawal of
participation
Participants who consent to take part in the study but
later decided they do not want to go forward into the
trial, or leave before the intervention/TAU is complete,
will be contacted and asked their reasons for not partici-
pating. For participants in the COPESS arm of the feasi-
bility trial, therapy will continue if they choose to
withdraw from the research element of the project.
Where possible, data already collected will continue to
be used. The reasons why participants withdrew from
the study will be documented where possible. GPs will
be informed of patient withdrawal and/or if a patient
ceases communication with the study team. All feedback
on non-participation or withdrawal will inform a future
full trial design.
Randomisation and blinding
Following the collection of baseline data, eligible and
consenting participants will be randomly allocated (1:1)
by the study statistician, to receive COPESS plus TAU
or TAU alone. An algorithm within STATA 15 will be
used to generate random allocation sequences in blocks
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of size of 4 or 6. Block sizes will occur with equal fre-
quency and will be determined at random. The statisti-
cian generating the randomisation schedule will be
independent from other elements of the project to main-
tain allocation concealment. Blinding is an important
methodologic feature of an RCT that aims to reduce bias
[34]; however, in psychotherapy trials, complete blinding
is not possible as the participants cannot be blind to
whether they receive therapy or not. Participants will be
reminded to keep the researcher blind to their allocation
arm of the study. Once randomisation has taken place
the statistician will inform the study PI of patient arm al-
location. The PI will inform both the patient and their
GP, keeping the researcher completing study assess-
ments masked to treatment allocation. This will be facili-
tated by briefing members of the research team and
participants on the need to avoid disclosure of treatment
details (see Fig. 2). A record will be kept of how many
times accidental unblinding occurs. See Fig. 3 for full
timeline of events.
Sample size
A conventional power calculation is not necessary to
achieve the stated aims of this feasibility study, as we will
not be formally testing the effectiveness of the interven-
tion. Instead, we aim to recruit 60 participants, following
recommendations that this is sufficient to assess feasibil-
ity outcomes and estimate key parameters, such as the
standard deviation of potential outcomes, with adequate
precision in order to inform the sample size for a defini-
tive full trial [38, 39]. For example, with N = 60, an attri-
tion rate of up to 35% can be determined to within 12
absolute percentage points with 95% confidence. To
avoid high attrition rates, we will keep participants en-
gaged via text and/or telephone reminders.
Interventions
COPESS plus TAU
COPESS consists of four 50-min weekly sessions of face
to face or remote psychological therapy. A further
follow-up session is offered 4 weeks after the end of
therapy. Therapy is usually completed within 8 weeks,
but variations from the expected schedule, associated
reasons and drop-out rates will be monitored. Mersey
Care NHS Foundation Trust will train five of their
current therapists (Mental Health Nurses and Assistant
Psychologists) in the COPESS therapy. The therapy in-
volves working collaboratively with a patient to identify
patterns or conflicts in emotional experiences and inter-
personal relationships, linked to depressed mood and
acts of self-harm. The therapist works with the patient
to build a shared understanding of these experiences.
The first session will focus on the participant’s most re-
cent episode of self-harm and the interpersonal events
that precipitated the episode, and the participant’s asso-
ciated low mood. Risk assessment and safety planning
will also be incorporated into the initial session. The
three remaining sessions will focus upon the links be-
tween mood, relationship difficulties and self-harm. PIT
techniques include picking up cues, staying with and ex-
ploring feelings about relationships and interpersonal
problem-solving in the here and now. CAT techniques
will be used to help the participant to map out and
understand the reciprocal nature of relationships.
Due to the on-going impact of COVID-19 participants
in the intervention arm will have the option of remote
(via an online method such as Zoom or Skype or the
telephone) or face-to-face therapy sessions in the partici-
pant’s home or in a community setting, once pandemic-
related restrictions allow this option. There may be a dif-
ference in effectiveness of the intervention depending on
whether COPESS is delivered remotely or face to face,
Fig. 2 Randomization flow chart
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and this will be assessed via comparison of quantitative
data outcomes and through qualitative interviews. This
choice will be solely participant preference and will not
be part of the randomisation process. Safety for the
therapist/researcher and/or mobility for the patient will
be reviewed throughout the recruitment period.
We will calculate and present in a CONSORT [35]
flow chart: the proportion of people with depression and
Fig. 3 Summary of the sequence of study-related assessments, procedures and activities
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self-harm consenting to the study; the proportion com-
pleting the baseline assessment and entering the rando-
mised phase; the number of therapy sessions attended
and the proportion completing all sessions; the propor-
tion completing follow-up assessments at 4, 8 and 12
weeks post-randomisation.
Treatment-as-usual (TAU)
There will be no restrictions on care provided as TAU.
Participants randomised to TAU will be provided with
information about how to refer to local statutory or
non-statutory services and GPs will be encouraged to
follow the NICE guidance on care for people who self-
harm.4
Therapy fidelity and adherence
COPESS will be delivered by five therapists. Therapists
will receive a combined Psychodynamic Interpersonal
Therapy (PIT) and Cognitive Analytic Therapy (CAT)
Level 1 training. This is a 5-day short course that intro-
duces the principles of working with PIT and CAT and
the application within clinical practice. Ongoing supervi-
sion from a Lead Mental Health Practitioner will occur
on a fortnightly basis. If the standard therapy approach
is not being adhered to, therapists will be offered feed-
back. All sessions will be recorded with the consent of
participants. A subset of 10% of recorded sessions will
be rated by an independent psychotherapist with experi-
ence of the approach using a modified version of the
Sheffield rating scale [40] to ensure adherence to the ap-
proach. Each therapist will see approximately six partici-
pants (anticipated maximum range 4–8).
Primary outcome
The primary outcome of this feasibility study is the feasi-
bility and acceptability of using COPESS for people in
the community who self-harm and have co-existing de-
pression. Feasibility will be defined as the ability to re-
cruit the target sample size and retain at least 70% of
participants in both arms of the trial over the 3 -month
follow-up period. Acceptability of the intervention will
be assessed by the percentage of participants who engage
and are retained in therapy (acceptability requires > 40%
randomised to COPESS to attend all sessions) with con-
textual data collected from semi-structured qualitative
interviews focusing on participants’ experience of the
therapy. Acceptability of the intervention for therapists
will also be assessed by semi-structured qualitative inter-
view. Acceptability of the trial measures will be defined
as the proportion of participants who complete each of
the measures at all assessment points (acceptability re-
quires at least 80% of questionnaires completed), supple-
mented by semi-structured interview data.
Secondary outcomes measures
Participants will complete a batch of standardised ques-
tionnaires at follow-up assessments (see below) to be
conducted at 4, 8 and 12 weeks post-randomisation
(Table 1 shows the full assessment schedule). Partici-
pants will be invited to follow-up assessments unless
they have completely withdrawn from the feasibility trial.
Questionnaires used for the secondary outcome mea-
sures will help to:
a) Assess the feasibility of delivering these measures
within an RCT context;
b) Assess rates of missing data as this will inform the
use of these outcomes in a full trial;
c) Estimate variance in these outcomes as this will
guide the power calculations for the full trial.
Self-Injurious Thoughts and Behaviours Interview Short-
Form (SITBI)
The SITBI is a brief interview-based measure that uni-
formly assesses the presence, frequency and characteris-
tics of information on self-harm related thoughts and
behaviours. Repeated self-harm during the feasibility trial
period will be captured within the interview. The SITBI
has demonstrated interrater reliability, test-retest reli-
ability and convergent validity [41].
Beck Depression Inventory-II (BDI II)
The BDI II is an established self-report measure of de-
pressive symptoms over the past 2 weeks. There is evi-
dence for the reliability and validity of this measure in
the general population [36, 42]. Each of the 21 items on
the questionnaire has a choice of four answers scored
from 0 to 3. A combined score 0–13 is considered min-
imal depression, 14–19 mild depression, 20–28 moder-
ate depression and 29–63 severe depression. The
questionnaire takes approximately 10 min to complete.
Frequency/Intensity of self-harm urges-Alexian Brothers
Urge to Self-Injure Scale (ABUSI)
The ABUSI is a validated tool designed to evaluate the
frequency and intensity of urges to self-injure over the
past 7 days [43]. The scale has demonstrated good psy-
chometric properties. The scale measures urge, regular-
ity and strength of self-injurious thoughts across five 7-
point scales. Higher scores (up to a maximum of 30) in-
dicate a stronger desire to self-harm.
Emotion Regulation Questionnaire (ERQ)
The ERQ is a widely validated ten item questionnaire
that assesses the way in which individuals regulate their
emotions, including the use of re-appraisal and suppres-
sion of emotions [44]. The scale has demonstrated good
psychometric properties. Higher scores (up to a
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maximum of 70) indicate greater use of a particular
regulation strategy.
Clinical Outcomes in Routine Evaluation (CORE-10)
The CORE-10 is widely validated, brief ten-item meas-
ure of psychological distress over the past 7 days [45].
Higher scores signpost higher levels of psychological dis-
tress. A combined score of less than 10 falls in the non-
clinical range, 11 to 14 indicates mild psychological dis-
tress, 15 to 19 moderate psychological distress, 20 to 24
moderate psychological distress and 25 or above indi-
cates severe psychological distress.
The Helping Relationship Questionnaire (HRQ)
The HRQ is an 11-item questionnaire that measures pa-
tient’s perception of the therapist-patient relationship
[46]. The questionnaire is validated and has established
psychometric properties. The questionnaire uses a six-
point scale, with higher total scores indicating greater
therapeutic alliance
EQ-5D
The EQ-5D-5L is a validated six-item questionnaire
measuring quality of life across five health dimensions
(mobility, usual activities, self-care, pain/discomfort and
anxiety/depression). Five items are measured on a five-
point scale considering health that day. The final ques-
tion asks individuals to signpost their health today on a
100-point scale (with zero indicating the worst health
imaginable and 100 indicating the best) [47].
The Client Service Receipt Inventory (CSRI)
The Client Service Receipt Inventory (CSRI) [48] will be
used to collect healthcare resource use. This includes in-
formation on use of other primary and secondary care
services, use of social services, disability payments re-
ceived, personal costs related to mental health (e.g. ex-
penditure on over-the- counter medication, expenditure
on prescriptions), time off work and unpaid activities.
Statistical analysis
As a feasibility study, we will not be carrying out hy-
pothesis testing to determine if the intervention is effect-
ive. Data analysis will follow an Intention-To-Treat
(ITT) protocol and will help inform power calculations
for a future definitive COPESS trial. Attrition and rea-
sons for drop-out will be recorded where possible. Ther-
apists will keep records of the number of COPESS
sessions participants attend and the researcher will
monitor and record the same information for the data
collection sessions. For participants who withdraw from
the study, the researcher will follow-up with either the
therapists or participants to record the reason(s) for
study withdrawal. We will assess rates and types of miss-
ing data, and proportion of dropouts at different stages/
pathways through the trial. We will also assess whether
any of the measures display floor and/or ceiling effects.
Guidance will be sought from the PAG on how to man-
age and minimise missing data and attrition over the
study period (see earlier section further details on the
role of the PAG).
Summary statistics will be used as appropriate (e.g.
mean/standard deviation; median/inter-quartile range;
proportion/ 95% confidence interval; data range) to de-
scribe and compare data for all participants on continu-
ous scores for repetition of self-harm, depressive
symptoms, and urges to self-harm, overall and by group.
The range and standard deviation of secondary outcome
measures, along with estimated attrition rate and average
number recruited per practice, will be help inform sam-
ple size calculations for a future full-scale trial.
Health economic analysis
The feasibility study will be used to develop a framework
for a subsequent cost effectiveness analysis to be under-
taken alongside a future RCT. In particular, economic
evaluation methods will be developed and tested regard-
ing the collection of resource use, costs and outcome
data. Health care resource utilisation and absences from
Table 1 Timing of outcome measurement
List of questionnaire Baseline Follow-up 1 Follow-up 2 Follow-up 3
Demographic information X
ABUSI X X X X
AEP Form (A/B) X X
Beck Depression Inventory X X X X
CORE-10 X X X X
ERQ X X X X
EQ-5D X X
HAq-II X X X X
SITBI 2.1 X X X X
CSRI X
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work will be collected for each patient during the study
follow-up period using the CSRI questionnaire. Data
from the feasibility study will be used to inform adapta-
tion of the CSRI prior to a definitive full trial. Generic
health-related quality of life (HRQoL) data will be col-
lected using the EQ-5D-5L instrument.
Qualitative study
At the time of feasibility trial consent, all participants
will be asked if they are willing to be contacted for pos-
sible participation in a one-to-one interview. In-depth
interviews will be conducted with participants from both
arms of the feasibility trial at 4–8 weeks post-
randomisation. The project adopts a comprehensive
safety protocol which guides the management of risk
and responses to experiences of distress. This protocol
was developed jointly by researchers, clinicians and indi-
viduals with lived experience of self-harm. An experi-
enced mental health researcher will conduct the
interviews and assessments. The researcher will receive
regular supervision from an experienced qualitative
researcher.
We also aim to include participants who did not at-
tend all COPESS therapy sessions. A purposive sample
of participants will be interviewed to capture maximum
variation in views and experience of those participating
in the study. Sampling parameters will include (1) socio-
demographic variables, (2) type of self-harm (injury or
poisoning) and (3) feasibility trial arm allocation. Partici-
pants will be selected from both arms of the feasibility
trial to provide an insight into experiences of COPESS
and TAU, and to allow for comparison of these experi-
ences. The interviews will assess understanding of, and
acceptability of the intervention received (content and
contexts, setting, etc.), perceived benefits and mecha-
nisms of action, challenges to engagement and context-
ual factors seen to affect the impact of intervention. For
participants in the TAU arm, the researcher will ask
about their experience of trial participation with a focus
on feasibility, study procedures and issues that may
affect attrition and feasibility of a larger trial. Addition-
ally, the researcher will explore the patient’s experience
of mental health pathways within the NHS to date and
whether they were aware of the COPESS intervention.
Interviews will be analysed in batches and sampling will
continue until no new themes emerge—we expect this
to be around 16–20 interviews.
GPs at participating recruitment sites will be invited to
be interviewed about their experience of recruiting par-
ticipants for this study. Therapists will be invited to be
interviewed about their experience of being trained in
the therapy and delivering the therapy. These interviews
will help gain a detailed understanding of the perceived
effectiveness and acceptability of the treatment,
implementation challenges, and any barriers to its up-
take in a community setting. Interviews will last approxi-
mately 60 min, will be audio-recorded and transcribed
verbatim. All transcripts will be anonymised.
Qualitative data analysis
Transcripts of interview data will be analysed via The-
matic Analysis using the framework approach [49].
Framework analysis was developed to meet information
needs and to provide practical outcomes and recommen-
dations [50]. It offers a highly visible and systematic ap-
proach to data analysis, showing very clearly how
findings are derived. Analysis will follow the five stages
of framework analysis; familiarisation with the data;
identifying a thematic framework; indexing the data;
charting the data; and mapping and interpretation [51].
To monitor and limit the possible bias of a single-
analyst perspective, additional members of the research
team with experience in qualitative methods will exam-
ine a sample of transcripts to compare their perceptions
of the interview data and analysis with the main analyst’s
interpretation. Themes will be discussed and refined fur-
ther in multidisciplinary research team meetings.
NPT [31] provides a framework for understanding the
barriers and facilitating processes that underlie the im-
plementation and integration of complex interventions
into healthcare systems. This will help make sense of the
qualitative data and draw conclusions relating to how
readily COPESS might be implemented and embedded
into health care systems [31, 51]. The theory identifies
four key processes that underlie the adoption of new in-
terventions; coherence of intervention; cognitive partici-
pation; collective action; and reflexive monitoring.
Previous research has shown that NPT can be applied
effectively to qualitative data in healthcare contexts to
aid interpretation [52]. NPT will be used to map the
links between qualitative themes and the core processes
outlined in NPT. This process will be aided through use
of the NPT toolkit (normalizationprocess.org) and appli-
cation of the NPT statements generated by May and col-
leagues [51]. To further promote integrity and rigor
during the data analysis process, field notes will be writ-
ten immediately after interviews and a reflective diary
maintained. Thus, aiming to reduce the potential for the
researcher’s values, beliefs and preconceptions to influ-
ence subsequent findings [31, 52].
Data handling
All confidential data will be stored securely on the Uni-
versity research centre site with strictly limited access.
Participants will be allocated an ID code which will be
used on documents such as questionnaires to maintain
confidentiality and minimise the use of personal data.
The feasibility trial Sponsor is Liverpool John Moores
Saini et al. Pilot and Feasibility Studies           (2021) 7:165 Page 9 of 12
University who takes primary responsibility for ensuring
that the design of the study meets appropriate standards
in accordance with Good Clinical Practice (GCP) guide-
lines. All data will be handled according to the General
Data Protection Regulation (GDPR) 2018. It was agreed
by the Project Steering Group that a Data Monitoring
Committee was not required due to the research being a
feasibility trial.
Safety monitoring
Adverse events and risk standardised operating proce-
dures will be developed and will be followed by all re-
searchers and therapists working on the feasibility trial.
Adverse events are defined as significant negative epi-
sodes, or significant deterioration in condition, which
happen to participants during their time in the feasibility
trial. These will be reported by research assistants and
trial therapists to senior trial staff, who will ascertain
whether these are thought to be linked to participation
in the feasibility trial, and keep records of each event on
an adverse events database. The Adverse Experiences in
Psychotherapy (AEP) self-report measure [53] will iden-
tify adverse experiences liable to occur within psycho-
logical therapy. All serious adverse events (SAE) of an
unexpected and unrelated nature will be reported to the
main Research Ethics Committee, the study Sponsor and
Trial Steering Committee (TSC). Suicide risk will be
closely monitored. If the individual is considered to be
high risk, the participant’s GP will be contacted and in-
formation passed to them within two working days. The
participant will also be given advice about local crisis
teams, and other relevant support services. In cases
where SAE are potentially linked to the feasibility trial,
withdrawal of participants, halting or terminating the
feasibility trial will be considered as required.
Discussion
The main purpose of this study is to examine the feasi-
bility (e.g. can we recruit) and acceptability (e.g. attend-
ance) of delivering COPESS in a community setting, and
the study procedures for a future full trial. The feasibility
trial will offer insight into cost-effectiveness of delivering
COPESS, a brief psychological therapy, within commu-
nity settings; a need that has been identified by clinicians
and researchers. Positive will help support the develop-
ment and a future full efficacy trial to assess how effect-
ive the intervention is at reducing depression and self-
harm.
There will also be benefits beyond the immediate feasi-
bility trial results. If COPESS proves to be an effective
intervention then this new model of care has the poten-
tial to be delivered more widely within the National
Health Service, as an effective, low cost, convenient, safe
and easily deliverable intervention.
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